These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22094668)

  • 1. Targeted treatment tested as potential cancer cure.
    Hayden EC
    Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
    [No Abstract]   [Full Text] [Related]  

  • 2. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
    Shi YK
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
    [No Abstract]   [Full Text] [Related]  

  • 4. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 5. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
    Costa DB
    J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
    [No Abstract]   [Full Text] [Related]  

  • 6. Crizotinib (xalkori) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2012 Feb; 54(1383):11-2. PubMed ID: 22354221
    [No Abstract]   [Full Text] [Related]  

  • 7. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
    Girard N
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.
    Mirshahidi HR; Mirshahidi S
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):375-85. PubMed ID: 25797684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

  • 12. In search of the philosopher’s stone: The ALCHEMIST study for lung cancer.
    Veeramachaneni N; Wigle D; Boughey JC
    Bull Am Coll Surg; 2017 Mar; 102(3):37-8. PubMed ID: 28920661
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
    Kotsakis A; Georgoulias V
    Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for lung cancer.
    Petrosyan F; Daw H; Haddad A; Spiro T
    Anticancer Drugs; 2012 Nov; 23(10):1016-21. PubMed ID: 22932130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
    Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
    J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ALK inhibitor].
    Sakamoto H
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):48-50. PubMed ID: 23842228
    [No Abstract]   [Full Text] [Related]  

  • 17. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
    Asai N; Yamaguchi E; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.